India Merger Acquisition MCA Regulatory Filings — October 20, 2026

NCLT Chennai sanction (Sep 30, 2026) received, ROC filing completed (Oct 15, 2026) satisfying Clause 24 conditionalities, and Board confirmed effectiveness; scheme is progressing on schedule with no reported obstacles

Authorized equity capital increase from ₹54.2 Cr to ₹74.2 Cr (total authorized ₹90 Cr to ₹110 Cr, +22%) creates headroom for the 23:2 share exchange issuance and signals committed execution of the amalgamation

23:2 exchange ratio (23 AGARWALEYE shares of ₹1 face value per 2 shares of ₹10 face value) implies roughly 11.5 consideration shares per legacy share; investors holding the Eye Hospital entity should evaluate the post-merger position against the Health Care stock on or before the November 18 record date

Appointed Date of April 01, 2026 means the economic benefit of operations transfers retrospectively, so the combined entity's results from April 2026 will be consolidated into post-effective-date reporting

Proposed US subsidiary via KSSPL with USD 510 initial subscription (51% stake) is immaterial to the listed entity's financials but signals an early step in international expansion in technology/IT services

Effective Date (Nov 01, 2026) and Record Date (Nov 18, 2026) are only weeks apart; any delay in ROC or exchange processing could compress the timeline and create short-term trading dislocation around record date

Transferor shareholders receive consideration shares at a 23:2 ratio, which implies significant share count expansion for the Health Care entity; the enriched data does not disclose pre- and post-merger share counts, so the dilution and per-share earnings impact cannot be quantified from these filings

Transferor company will be dissolved without winding up; legacy Eye Hospital listing will cease, requiring holders to act on share exchange and creating potential liquidity friction for smaller or retail holders

Incorporation of the US entity is explicitly subject to requisite approvals and the name, incorporation date, and 49% co-shareholder are unspecified, leaving execution and governance details open

The filings contain no period-over-period revenue, profit, margin, or debt metrics, and no insider transaction or guidance data, so the financial health of the combined entity cannot be validated from the enriched data alone

Scheme effective date Nov 01, 2026 and record date Nov 18, 2026 with a fixed 23:2 exchange ratio create a defined event-driven window for event-driven and merger-arbitrage investors to evaluate the spread between the Eye Hospital share price and implied value of consideration shares

Consideration share issuance will change the Health Care entity's free float and share count, likely triggering index weight and passive-fund rebalancing around the effective date; investors can position ahead of these flows

Combining the eye hospital business into the listed Health Care vehicle with retrospective Appointed Date (April 01, 2026) simplifies group structure and may improve capital-raising flexibility given the expanded authorized capital

Establishment of a US technology subsidiary via KSSPL signals the company's pivot toward IT and international growth; monitor the next disclosure for the entity's name, incorporation, and investment scale to gauge whether the expansion broadens into a material business line

Dr. Agarwal's group is simplifying a listed-and-unlisted structure by merging the eye hospital operations into the listed healthcare parent; this pattern of consolidation can unlock valuation through single-listing liquidity and clearer capital allocation across the group

The April 01, 2026 Appointed Date with a November 01, 2026 Effective Date (about seven months lag) is a standard NCLT mechanism that shifts economic benefit back to the appointed date; investors should expect restated comparative results in upcoming financial statements

Consolidation transactions are being executed through share-swap structures that require authorized capital increases (here +22% in total authorized capital), a recurring pattern in Indian MCA-sanctioned mergers that flags potential near-term dilution

Multiple duplicate filings (four of five) for the same Agarwal scheme over a short window reflect the Reg 30 and Reg 42 disclosure requirements at each stage; this clustering inflates the apparent news flow and should be read as a single underlying event

Scheme effectiveness on November 01, 2026; watch for final Board or ROC confirmation and any last-minute NCLT or regulatory condition changes

November 18, 2026 record date for consideration share allotment under Reg 42; monitor for exchange notices on share allotment timing and eligibility

Watch for announcements on delisting of the Transferor entity and the mechanics for shareholders to convert holdings into AGARWALEYE shares

First consolidated disclosures reflecting the April 01, 2026 Appointed Date will show the combined revenue and profit base; compare against standalone figures for mix and margin impact

Follow-up filing to confirm incorporation, entity name, regulatory approvals, and the 49% co-shareholder identity

Watch for the ROC filing confirming the increase in authorized share capital from ₹90 Cr to ₹110 Cr, as completion is a precondition for the consideration share issuance